Since the 1990s, we’ve seen an expansion in the gene therapy landscape, which is expected to continue growing in the coming years. (Cell Stem Cell) The global gene therapy market was valued at $6.0 billion in 2020 and is projected to reach $46.5 billion by 2030, growing at a CAGR
Approximately 25% of individuals aged 25 and above may face a stroke during their lifetime. (WSO) Strokes can result from a blocked artery, also known as Acute Ischemic Stroke (AIS), causing severe brain damage, disability, or death. (CDC). Since 1987, only one FDA-approved drug, a thrombolytic agent, has been used
In recent years, businesses in industries like life sciences and biotech have embraced digital communication. This has led to hybrid work environments, virtual conferences, and the recognition of social media as a valuable tool. Scientists and investors more actively participate in social media platforms, especially LinkedIn, making it crucial for
2023 was a challenging year for the biotech industry. We collaborated with a diverse set of clients, each at varying stages of their fundraising endeavors. As we reflect on the past year, we’d like to take a moment to highlight the impressive milestones our clients have reached. Lexeo Therapeutics Lexeo
If you are developing an innovative treatment or cutting-edge therapeutics platform, you are familiar with the challenge of raising funds. Biotech and life science companies offer higher ROIs, but also higher investment risks, especially in the early stages. Hence, the challenge – how do you convince investors that your approach
What makes science both captivating and complicated is its intricacies. This can pose a challenge when it comes to communicating with investors because a minor detail can have a major impact. Most of our clients have a differentiated or novel mechanism of action (MOA), but the challenge is how to
Fundraising never stops in biotech, which is why company leaders need to continually refine their fundraising strategies. In this article, we are highlighting the top 3 mistakes we see biotech companies make when pitching to investors. These three key mistakes came up during a recent appearance by our CEO and
Chimeric antigen receptor (CAR) T-cell therapy has shown significant promise in fighting blood cancers. Some studies indicate 9 of 10 people with acute lymphoblastic leukemia treated with CAR-T therapy experienced full remission. Since 2017, the FDA has approved 6 CAR-T therapies to treat blood cancers, including lymphomas, leukemia, and multiple
Unlike other industries, biotech companies require multiple funding cycles to fuel meticulously planned clinical trials that take more than a decade to complete. Biotech companies can’t pause development or quickly pivot to a more profitable product during difficult times. The necessity to continue clinical development of their therapeutics is why
For first-time CEOs who’ve recently made the transition from academia to entrepreneurship, building a successful biotech startup goes well beyond realizing their first rounds of funding.
A groundbreaking discovery, shifting milestones, and a rebrand made the Opna Bio project an exciting and dynamic endeavor for everyone involved. Opna Bio is a clinical stage company focused on the discovery and development of innovative oncology therapeutics. It was formed around the groundbreaking new discovery of a novel oncology
There is no surprise that life sciences field is very competitive, some areas more than others. It is a great challenge for up and coming life science companies to differentiate themselves among established competition, and – more importantly – communicate competitive advantages to investors. Naturally, scientists turn to data comparison
Growing life sciences companies require significant investment to stay afloat. And oftentimes the confidence in the company’s potential depends on how clear and compelling the pitch deck is. When Theoria Creative develops a scientific presentation deck for clients, we give careful consideration to each slide; every word, graphic and high-level message must be clearly
Biotech and pharmaceutical companies have a unique growth trajectory compared to other industries. They require a lot of capital and years of trial-and-error to get their drug product to market. Those companies choosing to raise public capital encounter an additional challenge: frequent investor presentations at roadshows and investment conferences to
When presenting at high-stakes meetings — whether you are pitching to investors, soliciting partnerships or justifying value proposition at a healthcare conference — having an effective corporate presentation is imperative for a successful outcome. It’s no secret that our attention spans have become increasingly hard to capture. More than ever
In recent years, CEOs at behemoth organizations like Google, Amazon, and LinkedIn have been reconsidering the use of PowerPoint in meetings (Amazon has gone so far as to ban the program entirely). And if you’ve ever sat through a PowerPoint presentation and gotten to the end with no clear idea of what the
When Apellis Pharmaceuticals, the clinical-stage biopharmaceutical company, was faced with delivering a complex story to 100 potential investors, Steve Axon – Chief Business Officer – knew they needed help. “We had recently completed our IPO but we knew that our presentation, which was about a scientific breakthrough using the complement system,
At Theoria Creative we bridge the communication gap for our biotech and life sciences clients, enabling them to clearly and succinctly articulate their unique message and value when raising funds, soliciting partnerships, pitching at roadshows, or presenting to prospective buyers.
We share useful tips and company news in a monthly newsletter.
